200 related articles for article (PubMed ID: 32879263)
1. Prediction of Lethal Arrhythmic Events Through Remote Monitoring Using Heart Rate Variability Analysis in Patients with an Implantable Cardioverter Defibrillator.
Shirakawa Y; Niwano S; Oikawa J; Saito D; Sato T; Matsuura G; Arakawa Y; Kobayashi S; Nishinarita R; Horiguchi A; Ishizue N; Kishihara J; Fukaya H; Ako J
Int Heart J; 2020 Sep; 61(5):927-935. PubMed ID: 32879263
[TBL] [Abstract][Full Text] [Related]
2. Increase in heart rate precedes episodes of ventricular tachycardia and ventricular fibrillation in patients with implantable cardioverter defibrillators: analysis of spontaneous ventricular tachycardia database.
Nemec J; Hammill SC; Shen WK
Pacing Clin Electrophysiol; 1999 Dec; 22(12):1729-38. PubMed ID: 10642125
[TBL] [Abstract][Full Text] [Related]
3. Comparison of ventricular tachyarrhythmia characteristics in patients with idiopathic dilated or ischemic cardiomyopathy and defibrillators implanted for primary prevention.
Streitner F; Kuschyk J; Dietrich C; Mahl E; Streitner I; Doesch C; Veltmann C; Schimpf R; Wolpert C; Borggrefe M
Clin Cardiol; 2011 Oct; 34(10):604-9. PubMed ID: 21887690
[TBL] [Abstract][Full Text] [Related]
4. Ranolazine in High-Risk Patients With Implanted Cardioverter-Defibrillators: The RAID Trial.
Zareba W; Daubert JP; Beck CA; Huang DT; Alexis JD; Brown MW; Pyykkonen K; McNitt S; Oakes D; Feng C; Aktas MK; Ayala-Parades F; Baranchuk A; Dubuc M; Haigney M; Mazur A; McPherson CA; Mitchell LB; Natale A; Piccini JP; Raitt M; Rashtian MY; Schuger C; Winters S; Worley SJ; Ziv O; Moss AJ;
J Am Coll Cardiol; 2018 Aug; 72(6):636-645. PubMed ID: 30071993
[TBL] [Abstract][Full Text] [Related]
5. Sex Differences in Device Therapies for Ventricular Arrhythmias or Death in the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy (MADIT-CRT) Trial.
Tompkins CM; Kutyifa V; Arshad A; McNitt S; Polonsky B; Wang PJ; Moss AJ; Zareba W
J Cardiovasc Electrophysiol; 2015 Aug; 26(8):862-871. PubMed ID: 25929699
[TBL] [Abstract][Full Text] [Related]
6. QT interval variability and spontaneous ventricular tachycardia or fibrillation in the Multicenter Automatic Defibrillator Implantation Trial (MADIT) II patients.
Haigney MC; Zareba W; Gentlesk PJ; Goldstein RE; Illovsky M; McNitt S; Andrews ML; Moss AJ;
J Am Coll Cardiol; 2004 Oct; 44(7):1481-7. PubMed ID: 15464332
[TBL] [Abstract][Full Text] [Related]
7. Electrical Substrate Elimination in 135 Consecutive Patients With Brugada Syndrome.
Pappone C; Brugada J; Vicedomini G; Ciconte G; Manguso F; Saviano M; Vitale R; Cuko A; Giannelli L; Calovic Z; Conti M; Pozzi P; Natalizia A; Crisà S; Borrelli V; Brugada R; Sarquella-Brugada G; Guazzi M; Frigiola A; Menicanti L; Santinelli V
Circ Arrhythm Electrophysiol; 2017 May; 10(5):e005053. PubMed ID: 28500178
[TBL] [Abstract][Full Text] [Related]
8. Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies.
Baquero GA; Banchs JE; Depalma S; Young SK; Penny-Peterson ED; Samii SM; Wolbrette DL; Naccarelli GV; Gonzalez MD
J Cardiovasc Electrophysiol; 2012 Mar; 23(3):296-301. PubMed ID: 21955243
[TBL] [Abstract][Full Text] [Related]
9. Predicted benefit of an implantable cardioverter-defibrillator: the MADIT-ICD benefit score.
Younis A; Goldberger JJ; Kutyifa V; Zareba W; Polonsky B; Klein H; Aktas MK; Huang D; Daubert J; Estes M; Cannom D; McNitt S; Stein K; Goldenberg I
Eur Heart J; 2021 May; 42(17):1676-1684. PubMed ID: 33417692
[TBL] [Abstract][Full Text] [Related]
10. [Long-term outcome after cardioverter-defibrillator implantation in patients with Brugada syndrome].
Binbin Y; Jingping L; Bing Y; Minglong C; Jiangang Z; Kejiang C; Qijun S
Zhonghua Xin Xue Guan Bing Za Zhi; 2015 Aug; 43(8):690-4. PubMed ID: 26955725
[TBL] [Abstract][Full Text] [Related]
11. Variations of heart rate variability parameters prior to the onset of ventricular tachyarrhythmia and sinus tachycardia in ICD patients. Results from the heart rate variability analysis with automated ICDs (HAWAI) registry.
Wollmann CG; Gradaus R; Böcker D; Fetsch T; Hintringer F; Hoh G; Hatala R; Podczeck-Schweighofer A; Kreutzer U; Kamaryt P; Hauser T; Kersten JF; Wegscheider K; Breithardt G
Physiol Meas; 2015 May; 36(5):1047-61. PubMed ID: 25903155
[TBL] [Abstract][Full Text] [Related]
12. Ventricular tachyarrhythmias in patients receiving an implantable cardioverter-defibrillator for primary versus secondary prophylaxis indications.
Manuchehry A; Agusala K; Montevecchi M; Kadish A; Passman R
Pacing Clin Electrophysiol; 2011 May; 34(5):571-6. PubMed ID: 21208242
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up in patients with arrhythmogenic right ventricular cardiomyopathy.
Li CH; Lin YJ; Huang JL; Wu TJ; Cheng CC; Lin WS; Tuan TC; Chang SL; Lo LW; Hu YF; Chao TF; Chung FP; Tsai CF; Tsao HM; Chen SA
J Cardiovasc Electrophysiol; 2012 Jul; 23(7):750-6. PubMed ID: 22353378
[TBL] [Abstract][Full Text] [Related]
14. Induction of ventricular fibrillation rather than ventricular tachycardia predicts tachyarrhythmia recurrences in patients with idiopathic dilated cardiomyopathy and implantable cardioverter defibrillator for secondary prophylaxis.
Rolf S; Haverkamp W; Borggrefe M; Breithardt G; Bocker D
Europace; 2009 Mar; 11(3):289-96. PubMed ID: 19095687
[TBL] [Abstract][Full Text] [Related]
15. Predictors of VT/VF-occurrence in ICD patients: results from the PROFIT-Study.
Klein G; Lissel C; Fuchs AC; Gardiwal A; Oswald H; Desousa M; Pichlmaier AM; Lichtinghagen R; Geerlings H; Lippolt P; Niehaus M; Drexler H; Korte T
Europace; 2006 Aug; 8(8):618-24. PubMed ID: 16864615
[TBL] [Abstract][Full Text] [Related]
16. Ventricular tachycardia/fibrillation early after defibrillator implantation in patients with hypertrophic cardiomyopathy is explained by a high-risk subgroup of patients.
Alsheikh-Ali AA; Link MS; Semsarian C; Shen WK; Estes NA; Maron MS; Haas TS; Formisano F; Boriani G; Spirito P; Maron BJ
Heart Rhythm; 2013 Feb; 10(2):214-8. PubMed ID: 23041573
[TBL] [Abstract][Full Text] [Related]
17. Benefit of the Wearable Cardioverter-Defibrillator in Protecting Patients After Implantable-Cardioverter Defibrillator Explant: Results From the National Registry.
Ellenbogen KA; Koneru JN; Sharma PS; Deshpande S; Wan C; Szymkiewicz SJ
JACC Clin Electrophysiol; 2017 Mar; 3(3):243-250. PubMed ID: 29759518
[TBL] [Abstract][Full Text] [Related]
18. Implantable defibrillator event rates in patients with idiopathic dilated cardiomyopathy, nonsustained ventricular tachycardia on Holter and a left ventricular ejection fraction below 30%.
Grimm W; Hoffmann J Jü; Müller HH; Maisch B
J Am Coll Cardiol; 2002 Mar; 39(5):780-7. PubMed ID: 11869841
[TBL] [Abstract][Full Text] [Related]
19. Competing risk analysis of ventricular arrhythmia events in heart failure patients with moderately compromised renal dysfunction.
Goldenberg I; Younis A; Aktas MK; McNitt S; Zareba W; Kutyifa V
Europace; 2020 Sep; 22(9):1384-1390. PubMed ID: 32875313
[TBL] [Abstract][Full Text] [Related]
20. Sudden death in implantable cardioverter-defibrillator recipients: clinical context, arrhythmic events and device responses.
Pires LA; Lehmann MH; Steinman RT; Baga JJ; Schuger CD
J Am Coll Cardiol; 1999 Jan; 33(1):24-32. PubMed ID: 9935004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
